Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.57 |
| ▸ | NPY1R | P25929 | 5/20 | 0.57 |
| ▸ | NPY2R | P49146 | 3/20 | 0.57 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 2/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22339062 | 0.92 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL30548763 | 0.91 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7441309 | 0.90 | ITGB3 (0.46) | CALCRL | |
| SCHEMBL10168616 | 0.90 | APLNR (0.49) | NPY4RNPY5RNPY1RNPY2RPRKACB | |
| SCHEMBL29540539 | 0.90 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL29461967 | 0.90 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL10168278 | 0.88 | APLNR (0.49) | NPY4RNPY5RNPY1RNPY2RPRKACB | |
| SCHEMBL23750214 | 0.88 | APLNR (0.49) | NPY4RNPY5RNPY1RNPY2RPRKACB | |
| SCHEMBL22117541 | 0.87 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL22117539 | 0.87 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | NPY4R 4307/4885NPY5R 4617/4885NPY1R 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.